Do we know they are not reporting it? Perhaps we should wait and see.
The share price took a bath after the PFS readout. But it was noted at the time that results were better in different patient sub groups.
AIPAC OS data was reported in December last year( see below) which excited the market considerably. Since then, we have had extremely positive results in combination trials with Keytruda that have resulted in Fast Track designation for Efti in head and neck squamous cell cancer.
Please read the last data report from the AIPAC trial which explains why we are excited. Overall, patients are living longer with better quality of life than SoC and the trajectory was improving. And, equally importantly, Efti is safe.
Don’t delay, get on board if you are thinking about it. (Imo)
Do we know they are not reporting it?
Do we know they are not reporting it? Perhaps we should wait and...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.8¢ |
Change
0.008(2.34%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 31.8¢ | $222.1K | 688.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 204221 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 145285 | 24 |
View Market Depth
| Last trade - 11.36am 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |